The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
Wall Street's median 12-month price target for LivaNova PLC is $84.00, about 1.6% below its August 4 closing price of $85.33.
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 14 three months ago.
Quarterly results beat expectations
UK medical technology firm's Q2 revenue grew 10.8%, beating analyst expectations.
Adjusted EPS for Q2 also beat analyst expectations.
Company press release: ID:nBw6xkGmVa
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$390.60 mln
$380.76 mln (9 Analysts)
Q2 Adjusted EPS
Beat
$1.26
$1.10 (9 Analysts)
Q2 EPS
$1.93
Revenue drivers and supply agreement
Cardiopulmonary sales - Q2 Cardiopulmonary revenue rose, driven by growth in Europe, Essenz Perfusion System sales, strong consumables demand, and favorable realized price.
Neuromodulation growth - Q2 Neuromodulation revenue grew across all regions, driven by volume growth and favorable realized price.
Supply agreement - Co entered a long-term agreement with Thermo Fisher Scientific to increase oxygenator component availability and expand manufacturing output.
2026 outlook raised
LivaNova raises 2026 revenue growth guidance to 8%-9% on a constant-currency basis.
Company now expects 2026 adjusted diluted EPS of $4.30-$4.40.
LivaNova lowers 2026 adjusted free cash flow guidance to $140 mln-$160 mln.
LIVN•
